Kilitch Drugs (India) Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kilitch Drugs (India) Limited has submitted a disclosure under SEBI regulation 31(4) to the stock exchanges (BSE and NSE). The filing, signed by Mukund Mehta (Managing Director and Promoter), confirms that the Promoters and Promoter Group, along with persons acting in concert, have not created any encumbrance (pledge or charge) over their shares during the financial year ended 31st March, 2026. This is a routine compliance filing required to be submitted periodically by listed companies.
Positive signal for investors as it confirms promoters have not pledged their shares, reducing risk of forced selling pressure. This indicates promoter confidence in the company without financial strain on their holdings.